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Progress in multiples sclerosis (MS), since the pi-
oneering work of Charcot and his predecessors, has 
not occurred suddenly through dramatic scientifi c 
breakthroughs, but through the continued eff orts of 
thousand of investigators. Advances in understanding 
of basic science, particularly immunology and phar-
macology as well as developments in the investigation 
clinical disease, especially magnetic resonance imag-
ing, ultimately contributed to the approval of the fi rst 
drugs to impact the natural history of the disease. At 
the dawn of twenty-fi rst century, the availability of 
interferons and glatiramer acetate has accentuated the 
hopes of those aff ected with MS and their families.
Multiple sclerosis is and autoimmune neurological 
disease characterized by dissemination of changes in 
the CNS white matter in both time and space.
Historical overview of the events provides insight 
into the understanding of the disease and in many 
medical trends during last two centuries. 
Th e fi rst description of the disease is in St Lidwine 
van Schiedam who lived in late XIV and early XV 
centuries. Th e history of her ailment was described by 
Medaer. She was born on April 18 1380 in Schiedam, 
the Netherlands. Dr Sonderdank, the physician who 
had treated her, said to his colleagues: “Believe me 
when I tell you that this disease has no cure; it comes 
straight from God. Neither Hippocrates, nor Galen 
would be able to help here. Th is woman was touched 
by the hand of God”1.
A well documented case, before the disease was 
recognized in medical circles, is the case of Augustus 
d’Este (1794-1848), George III’s grandson. He had 
been writing a detailed journal since 1822 where he had 
described symptoms very graphically and followed the 
progression of his disease during several decades.
Another notable personality who is believed to 
have had multiple sclerosis was the poet Heinrich 
Heine (1797-1856).  
Charles Prosper Olliveier d’Auders was the fi rst to 
give an account of MS in a monograph published in 
Paris in 1824 in the work entitled “Maladies de la moelle 
epiniére”, where he described a twenty-year-old with 
relapsing-remitting neurological symptoms. Robert 
Carswell was the fi rst to describe pathologic changes 
of MS in an atlas published in 1838. In France Jean 
Cruveilhier had described four cases in a text entitled 
“Diseases of the spinal cord”. Charcot gives Cruveilhei-
ru the primacy as the fi rst MS illustrator. Carswell’s 
pictures appeared three years earlier. Th e fi rst clinical 
diagnosis of MS in a living patient had been provided 
by Frerich Th eodore von Frerich in 1849 2.
Jean-Martin Charcot (1825-1893) is without doubt 
the physician who is historically most associated with 
the MS. He described tremor, nystagmus and dysar-
thria, which came to be known as Chartcot’s triad. 
Across the Atlantic JC Morris was the fi rst to give 
and account of the disease in the USA in 1867. During 
the fi rst half of the XX century there was little true 
progress in the understanding and therapy of MS. All 
therapeutic eff orts were futile and non productive, fol-
lowing the fashion of the era. Th e medicaments were 
antispirochetal, antihystaminic, anticoagulant and a 
whole range of other agents. Th erapy with strychnine, 
silver, gold injections and electric stimulation were 
unsuccessful. 
In 1933 Rivers, Sprint and Berry gave very signifi -
cant contribution to the understanding of the disease 
development in animals, experimental autoimmune 
encephalomyelitis (EAE), which has served as the 
model for MS ever since.
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Th erapy of MS has remained unsuccessful during 
the whole 1960s.
In 1960 JF Kurtzke published a scale for assess-
ment of patients’ affl  iction by multiple sclerosis 3.
Augustus Rose carried out a study on ACTH in 
therapy of acute MS exacerbations. It was the fi rst suc-
cessful randomized, placebo controlled, multi-centric 
study of MS, as well as the predecessor of larger and 
more sophisticated studies of MS which have culmi-
nated in the development of new therapies in 1990s 
(4). In 1965 Schumacher off ered diagnostic guidelines 
for the needs of clinical trials. Th e development of 
electrophysiological methods (evoked responses) and 
neuroimaging (MRI), introduced in MS diagnosis 
in 1981, as well as increased recognition of the use 
of CSF analysis, has provided new, so called, Poser’s 
complex criteria for MS diagnosis 3.
Th e results of many studies using diff erent im-
munosuppressive medications have been published 
during 1980s. Th e majority of those medications have 
been shown to be successful in open, small, random-
ized studies, but provided only minimal eff ect in 
large, multi-centric, randomized, placebo controlled 
studies. Despite the failure of these studies to iden-
tify eff ective therapies, they served as a ground for 
training of many researchers who became extremely 
skillful in management of these very complex studies. 
Th e researchers in North America and Europe have 
carried out studies on interferons and glatiramer ac-
etate in 1990s, which led to their approval in 1993 
interferon beta-1b (Betaferon) became the fi rst drug 
approved for MS by FDA. In 1996 interferon beta-1a 
(Avonax) was approved in the USA5. In 1997 glati-
ramer acetate (Copaxone) was approved in the USA6. 
In 2000 Mitoxantron (Novantrone) became the fi rst 
drug approved for progressive MS in the USA.
In 2004 the FDA approved a drug called natali-
zumab (Tysabri) for the treatment of MS. Th e drug 
has been pulled off  the shelved a year later because 
of the brain infection in three patients, only to be re-
approved for treatment of recurrent-remittent form 
of MS in 20067. Alemtuzumab (Campath 1H) is a 
monoclonal antibody which has been used for treat-
ment of chronic lymphatic leukemia since 2001. In 
treatment of multiple sclerosis we use its activity on 
lymphocytes (T lymphocytes) in the patient’s blood. 
Th e drug is given in infusions, which are repeated 
after 12 and 24 months. Th ere are reports about ef-
fectiveness of a drug rituximab (Rituxan), also mono-
clonal antibody, which binds to CD20 and is located 
on the precursors of B-cells and mature B-cells; it is 
recommended for the treatment of the non-Hodgkin 
lymphoma, rheumatoid arthritis and B-cells lym-
phoma. Th ere are studies under way on the eff ect of 
daclizumab (Zenepax), a monoclonal antibody, which 
binds to CD25 on alpha chain of interleukin-2, thus 
infl uencing T-cells activity and proliferation. We are 
expecting soon two drugs for treatment of recurrent-
remittent multiple sclerosis: fi ngolimod (a sphingosine 
modulator) and Cladribine (a cytostatic with immu-
nosuppressive action, used in leukemia treatment)8. 
Due to a series of adverse eff ects, the treatment with 
blood stem cells after previous chemotherapy requires 
additional research.
Recently, a vascular surgeon, Dr Paolo Zamboni, 
from the University of Ferrara in Northern Italy, has 
published very interesting data on obstructions in 
brain-spinal venous fl ow (circulation). Th e wife of Dr 
Zamboni suff ers from MS, and that was the cause for 
him to dedicate so much attention of the disease. Us-
ing ultrasound and venography in examination of 65 
patients, he was able to detect 4 diff erent types (A, B, 
C and D) of obstruction in venous fl ow (circulation). 
Th e obstructions were in the form of stricture in neck 
venous system in diff erent places. As a consequence 
of the stenosis, most frequently in neck blood vessels 
and in the spinal area, there is a refl ux of the venous 
blood and the crash in the brain blood fl ow. Recur-
rent-remittent MS and primary advancing type of the 
disease are connected with stenosis in diff erent places 
in the venous fl ow. Th e expansion of those constricted 
places in the venous system and placement of stents 
managed to improve the blood fl ow. Treatment of the 
constrictions in venous system came to be known as 
“Liberation”. Th e obstructions of the venous blood 
fl ow are connected with iron depositing in the brain. 
Iron takes part in creation of free radicals, which act 
toxically on nerve cells. Symptoms of the disease in 
Dr Zamboni’s wife, who had diffi  culties with eye-
sight, balance and dramatic onset of the disease, have 
improved drastically. Treatment of more than 100 pa-
tients with acute relapse of the disease led to a fast 
improvement without the use of corticosteroids. Af-
ter the treatment the patients cite smaller disease re-
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lapses, a slight fatigue; there is less brain changes and 
the quality of life is improved. Th ere is an ongoing 
study at the University of Buff alo, New York. Perhaps 
the removal of obstruction in venous blood fl ow can 
enable us to successfully treat a certain number of pa-
tients with multiple sclerosis9.
Another key development in the history of MS was 
the founding in the United States of the National MS 
Society, originally called the Asssociation for the Ad-
vancement of Research in to MS in 1945. Th e estab-
lishment of this organization resulted from the tireless 
eff orts of Sylvia Lawry. She had been frustrated by her 
inability to fi nd help for her brother who was suff ering 
with MS. Th is was followed by establishment of the 
MS Society of Canada and then similar organizations 
in other nations. Th is moment has been a mainstay of 
research funding for disease, in addition to promoting 
improved care and advocacy for MS patients. In 1986, 
seven prominent MS centers founded Th e Consor-
tium of MS centers (CMSC) with the principal goal 
of improving the care of patients. Th is organization 
has since expended to an international group with 
over 200 MS centers among its membership. An or-
ganization composed of a wide variety of professionals 
caring for MS patients, it has served as forum for the 
exchange of information and resource for the develop-
ment of collegial relationships. Th e existence of the 
Consortium of MS centers has contributed greatly to 
the expansion of the number of committed individu-
als working in the fi eld, as well at to their retention in 
a very stressful professional area2.
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